Tysabri patent expiration?

See the DrugPatentWatch profile for Tysabri

What happens when the Tysabri patent expires?

As of my knowledge cutoff in 2023, the Tysabri patent is held by Biogen and Elan Pharmaceuticals. Tysabri, also known as natalizumab, is a medication used to treat multiple sclerosis and Crohn's disease.

When does the patent for Tysabri expire?

According to DrugPatentWatch.com [1], the patent for Tysabri expires on December 22, 2028. This date may be subject to changes or extensions due to various factors, such as patent disputes or FDA approvals for biosimilars.

Can biosimilars enter the market before the patent expires?

Under the Biologics Price Competition and Innovation Act (BPCIA) of 2009, biosimilars can be approved by the FDA before the patent expires. However, this approval does not guarantee market entry, as the patent holder may challenge the approval or negotiate pricing agreements with the biosimilar manufacturer.

How does this impact patients and healthcare providers?

The expiration of the Tysabri patent may lead to the introduction of biosimilars, which can potentially reduce treatment costs. However, patients may need to switch to a new medication, and healthcare providers may need to adjust treatment plans accordingly.

What are the potential implications for Biogen and Elan Pharmaceuticals?

The expiration of the Tysabri patent may impact the revenue of Biogen and Elan Pharmaceuticals. The companies may need to adapt their business strategies to remain competitive in the market, including through the development of new medications or partnerships with biosimilar manufacturers.

References:

[1] DrugPatentWatch.com. (n.d.). Tysabri (Natalizumab) Patents. Retrieved from https://www.drugpatentwatch.com/DrugPatents/10395

Sources:

Note: This answer relies on publicly available data and may not reflect any changes or updates since my knowledge cutoff in 2023.